Adela Perolla, MD, PhD, is a hematologist at the University Hospital Center "Mother Teresa" in Tirana, Albania.

Panelists discuss how current therapeutic strengths include 15 approved treatments with different mechanisms of action that ...

Panelists discuss how emerging intrathecal gene therapy for older patients with spinal muscular atrophy (SMA) shows modest ...

Panelists discuss how comorbidities such as scoliosis, dislocated hips, and nutritional issues affect spinal muscular atrophy ...

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, ...

Both monotherapy and combination therapy containing epcoritamab had high response rates and survival benefits when compared ...

Ola Landgren, MD, PhD, lead investigator of the ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches.

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological ...

In contrast, when using the traditional race-adjusted creatinine-based equation (eGFRcr-ASR), the HR was 2.8 (95% CI, 1.6–4.9 ...

This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for ...

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.